Cancer Prevention Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference

FAP is a rare genetic disease that if left untreated progresses to colorectal cancer in nearly 100% of patients. In June, an Independent Data Monitoring Committee (IDMC) recommended continuation of the Phase 3 trial following a planned interim futility analysis. In September, the U.S. Food and Drug Administration granted CPP-1X/sul “fast track” status, potentially speeding regulatory approval and commercialization.

In 2016 CPP signed a collaboration agreement with Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) that grants Sucampo the sole option to acquire an exclusive license to commercialize CPP-1X/sul in North America. Sucampo recently highlighted CPP-1X/sul during their 2017 R&D Day in New York City.

For more information on the FAP clinical trial (CPP FAP-310), please visit: https://clinicaltrials.gov/ct2/show/NCT01483144.

About Cancer Prevention Pharmaceuticals, Inc.

Cancer Prevention Pharmaceuticals, Inc. (CPP) is developing therapeutics designed to reduce the risk of cancer and other diseases. CPP’s pharmaco-prevention approach has been used with success in other disease categories such as cardiovascular, neurovascular, and infectious disease. In addition to the FAP-310 trial, CPP is co-sponsoring with the National Cancer Institute (NCI) and SWOG a large Phase 3 trial in colon cancer survivors. CPP is also working collaboratively with nonprofit groups to support their clinical trials in neuroblastoma, gastric cancer, and early-onset type 1 diabetes. CPP is located in Tucson, Arizona. For more information, please visit http://canprevent.com.

For more information on the clinical trial (CPP FAP-310), please visit: https://clinicaltrials.gov/ct2/show/NCT01483144.

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the benefits of Fast Track Status. These forward-looking statements represent the company’s judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.